Swender David A, Chernin Leah R, Mitchell Chris, Sher Theodore, Hostoffer Robert, Tcheurekdjian Haig
University Hospitals, Cleveland, Ohio, ; Richmond Medical Center, Richmond Heights, Ohio.
Allergy Rhinol (Providence). 2012 Fall;3(2):e55-60. doi: 10.2500/ar.2012.3.0034. Epub 2012 Dec 12.
Allergy skin testing is considered a safe method for testing for IgE-mediated allergic responses although anaphylactic events can occur. Reported rates of anaphylaxis per patient are not consistent and range from 0.008 to 4%. The aim of this study was to determine the rate of epinephrine use associated with allergy skin-prick testing (SPT) and intradermal testing (IDT) in a suburban practice over 13 years. This retrospective chart review used billing and procedure coding records during the time period from January 1997 to June 2010 to identify encounters where epinephrine was administered after SPT or IDT. Patient encounters with procedure codes for skin testing plus either parenteral epinephrine, corticosteroid, antihistamine, or i.v. fluid administration were identified. These patient charts were reviewed to determine if epinephrine was administered, whether systemic reactions developed, and rates of epinephrine administration were calculated. There were 28,907 patient encounters for SPT and 18,212 for IDT. Epinephrine was administered in six patient encounters (0.02%) where SPT was performed; no IDT encounters led to epinephrine administration. There were no fatalities. Allergy skin testing to a variety of allergens, when administered by well-trained personnel, is a safe procedure. This study, involving the largest population to date, showed a rate of systemic reactions requiring epinephrine of 20 per 100,000 SPT visits. No epinephrine was given after IDT.
尽管可能会发生过敏反应事件,但过敏皮肤试验被认为是检测IgE介导的过敏反应的一种安全方法。报告的每位患者过敏反应发生率并不一致,范围在0.008%至4%之间。本研究的目的是确定在13年期间郊区诊所中与过敏皮肤点刺试验(SPT)和皮内试验(IDT)相关的肾上腺素使用发生率。这项回顾性图表审查利用了1997年1月至2010年6月期间的计费和程序编码记录,以识别在SPT或IDT后使用肾上腺素的情况。确定了具有皮肤试验程序编码以及肠胃外肾上腺素、皮质类固醇、抗组胺药或静脉输液给药的患者就诊情况。对这些患者图表进行审查,以确定是否使用了肾上腺素、是否出现全身反应,并计算肾上腺素使用发生率。有28907例患者进行了SPT,18212例进行了IDT。在进行SPT的6例患者就诊情况(0.02%)中使用了肾上腺素;没有IDT就诊情况导致使用肾上腺素。没有死亡病例。由训练有素的人员进行的针对多种过敏原的过敏皮肤试验是一种安全的程序。这项涉及迄今为止最大人群的研究表明,每100000次SPT就诊中需要使用肾上腺素的全身反应发生率为20例。IDT后未使用肾上腺素。